Clinical Trials Browser

Phase 3 × Completed × Photopheresis × Clear all

NCT03112603 2025-08-12

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Phase 3 Completed

330 enrolled 32 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease